Here's a concise, retail-friendly summary: **Business Performance:** Themis Medicare faced significant headwinds from its high-margin formulations business.

Q2 FY26 revenue fell to ₹78 Cr (-33.3% YoY), with PAT down 125.3%. H1 revenue declined 26.8% YoY, and PAT dropped 145.8%. Positively, H1 API business grew 31% YoY, and Trade business rose 4%. A regulatory investigation impacts a key business line. **Growth Drivers & Strategy:** The company targets Hospital business leadership, focusing on high-margin brands.

Strategies include improving operational efficiency, cost optimization, and strengthening R&D for differentiated products in critical therapeutic areas. **Recent Developments:** A regulatory investigation concerning a major high-margin business is ongoing, with a positive resolution expected by March 2026. **Key Financial Metrics:** Q2 FY26 Revenue: ₹78 Cr.

H1 FY26 API business: +31% YoY.

R&D investment: 3% of revenue. **Management Commentary & Outlook:** Management expressed "cautious optimism," anticipating the regulatory matter to resolve positively.

Plans include expanding into new international markets (CIS, LatAm, GCC initially; EU, USA later) and continued R&D investment.